Gladius Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Gladius Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-727	Closed	-$39.4K	–	311
2024 Q1	$39.4K	Buy	+727	New	+$37K	0.01%	213
2022 Q3	–	Sell	-1,404	Closed	-$109K	–	383
2022 Q2	$109K	Sell	1,404 -7,218	-84%	-$550K	0.01%	192
2022 Q1	$630K	Buy	8,622 +6,219	+259%	+$418K	0.05%	90
2021 Q4	$150K	Buy	+2,403	New	+$141K	0.01%	209
2021 Q2	–	Sell	-1,186	Closed	-$75K	–	140
2021 Q1	$75K	Buy	+1,186	New	+$73.8K	﹤0.01%	161

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gladius Capital Management's BMY Position: Q2 2024 in Review

Gladius Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 727 shares — an estimated $39.4K sold.

Gladius Capital Management first reported a position in BMY in Q1 2021 and held it in 5 quarters. The position peaked at $630K in Q1 2022. 2,154 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Gladius Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Gladius Capital Management sold 727 Bristol-Myers Squibb shares in Q2 2024, an estimated $39.4K.
Gladius Capital Management first reported a position in Bristol-Myers Squibb in Q1 2021 and held it in 5 quarters.
Gladius Capital Management's Bristol-Myers Squibb position peaked at $630K in Q1 2022.
2,154 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Gladius Capital Management's 13F filing for Q2 2024, filed 18 Jul 2024.